Dhuwit awis perusahaan: Genprex Inc. (GNPX)

GNPX (Genprex Inc.) - tandha merek perusahaan

The cash balance reflects liquidity dynamics, with 0.01 representing the latest level. Genprex, Inc. is currently depleting its available reserves due to oncology research expenditures. Risks are increasing due to a reliance on Asian supplies and logistics. Additionally, the company faces intense pressure from corporate behemoths seeking to monopolize the gene therapy market.

Genprex Inc. - Sisa dhuwit perusahaan GNPX (periode 04.07.2022 - 21.11.2026)

Genprex (GNPX) - rincian metrik lan laporan keuangan

- indikator kapitalisasi bursa perusahaan:
Analisis fundamental perusahaan:genprex.com GNPX
Produk mawa merek genprex.com

This indicator measures liquid reserves, determining the business's ability to maintain operational stability and fund growth without relying on external borrowing. By analyzing current cash reserves, an investor assesses the capital management efficiency of Genprex, Inc. (GNPX), where sufficient funding is critical for realizing the patent potential of the OncoPrex platform and scaling innovative R&D programs in cancer therapy.

Pesaing utama

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Xilio XLO|Volume dana dhuwit perusahaan RENB (Renovaro)|Volume dana dhuwit perusahaan Mural Bio MURA|Kairos Pharma Ltd - Volume dana dhuwit perusahaan|OnKure Therapeutics (OKUR) - Dhuwit awis perusahaan|GDTC: Volume dana dhuwit perusahaan|Curis Inc. - Sisa dhuwit perusahaan|Dana dhuwit perusahaan apollomicsinc.com|THAR: Sisa dhuwit perusahaan|Dana dhuwit perusahaan Advanced Biomed Corp (ADVB)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan